rs1867277 — FOXE1 c.-283G>A

Functional 5' UTR variant in the FOXE1 thyroid transcription factor that increases papillary thyroid cancer risk by recruiting USF1/USF2 transcription factors to upregulate FOXE1 expression

See your personal result for FOXE1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FOXE1 c.-283G>A — A Transcription Factor Switch That Tunes Thyroid Cancer Risk

FOXE1 (Forkhead Box E1), also known as thyroid transcription factor 2 (TTF-2), is one of the master regulators of thyroid gland development. It directs the migration and differentiation of thyroid precursor cells during embryogenesis and maintains thyroid identity in adult tissue. The rs1867277 variant sits 283 base pairs upstream of the FOXE1 translational start site, in a region that controls how much FOXE1 protein is made. Unlike most GWAS-identified risk variants whose functional mechanism remains unknown, rs1867277 has been directly proven to be a causal variant11 directly proven to be a causal variant
Landa et al. demonstrated through electrophoretic mobility shift assays and reporter gene assays that the A allele creates a functional transcription factor binding site absent from the G allele — one of the few thyroid cancer risk SNPs with a fully elucidated molecular mechanism.

The Mechanism

The c.-283G>A change alters a transcription factor binding motif22 transcription factor binding motif
A short DNA sequence recognized by transcription factors that control gene expression; a single nucleotide change can create or destroy these binding sites in the FOXE1 5' UTR. When the A allele is present, the sequence creates a binding site for USF1 and USF233 USF1 and USF2
Upstream Stimulatory Factors 1 and 2 — leucine zipper transcription factors that bind E-box elements and activate transcription. Co-transfection of USF1 and USF2 with the A-allele promoter construct produced an 8-fold increase in FOXE1 transcription44 8-fold increase in FOXE1 transcription
Compared to the G-allele construct, which did not respond to USF1/USF2 co-transfection compared to the G-allele construct. Both alleles form complexes with DREAM, CREB, and alphaCREM55 DREAM, CREB, and alphaCREM
Calcium-responsive and cAMP-responsive transcription factors that bind the FOXE1 promoter regardless of rs1867277 genotype, but the USF1/USF2 recruitment is exclusive to the A allele.

The paradox is that FOXE1 is generally considered a differentiation factor and even a tumor suppressor in some contexts — yet the A allele that increases FOXE1 expression is the risk allele. The resolution likely involves context-dependent FOXE1 activity: overexpression of FOXE1 in certain cellular states may promote epithelial-to-mesenchymal transition66 overexpression of FOXE1 in certain cellular states may promote epithelial-to-mesenchymal transition
FOXE1 has been shown to regulate ZEB1, a master EMT transcription factor, promoting migration and invasion in thyroid cancer cell lines and cell migration, contributing to tumor initiation or progression rather than suppression.

The Evidence

The original functional study by Landa et al. 200977 original functional study by Landa et al. 2009
Landa I et al. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genetics 2009 combined case-control association with functional characterization across two independent European populations (Spanish and Italian), totaling 984 papillary thyroid cancer cases and 1,028 controls. The combined per-allele OR was 1.49 (95% CI 1.30-1.70, P=5.9x10-9).

A meta-analysis of 16 studies encompassing 120,258 individuals88 meta-analysis of 16 studies encompassing 120,258 individuals
Chen GY et al. Common genetic variants on FOXE1 contributes to thyroid cancer susceptibility. Tumor Biology 2014 confirmed a random-effects per-allele OR of 1.62 (95% CI 1.50-1.76), with stronger effects in Caucasians than East Asians. A subsequent BMC meta-analysis of 15 studies99 BMC meta-analysis of 15 studies
Wang Y et al. Exploration of the association between FOXE1 gene polymorphism and differentiated thyroid cancer. BMC Medical Genetics 2018 reported OR 1.42 (95% CI 1.32-1.51), consistent with a moderate per-allele effect.

In Belarusian children exposed to Chernobyl fallout1010 Belarusian children exposed to Chernobyl fallout
Damiola F et al. Contribution of ATM and FOXE1 to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation. International Journal of Cancer 2014, rs1867277 was associated with radiation-related PTC (OR 1.55, 95% CI 1.03-2.34), confirming that this genetic background modifies susceptibility to radiation-induced thyroid cancer.

A Turkish study of histopathological correlates1111 Turkish study of histopathological correlates
Findings reported across multiple studies examining FOXE1 variants and tumor characteristics found that the AA genotype was significantly associated with more aggressive tumor features: capsular invasion risk increased 2.97-fold, lymph node invasion risk 2.46-fold, and advanced pathological stage (pT3/pT4) risk 4.13-fold compared to GG carriers. This suggests the variant influences not only cancer initiation but also tumor behavior.

Practical Implications

Papillary thyroid cancer is the most common thyroid malignancy, accounting for roughly 80% of all thyroid cancers. While it has an excellent prognosis when detected early (5-year survival above 98%), late-stage disease with extrathyroidal extension carries significantly worse outcomes. The rs1867277 AA genotype identifies individuals at both higher risk of developing PTC and potentially more aggressive disease.

The actionability centers on surveillance: individuals with AA genotype benefit from awareness and, when combined with other risk factors, from enhanced thyroid monitoring. Selenium supplementation supports thyroid antioxidant defense through selenoproteins (glutathione peroxidase and thioredoxin reductase) concentrated in thyroid tissue.

Interactions

This variant operates at the same chromosomal locus (9q22.33) as rs965513 and rs944289 but represents an independent signal. Conditional analysis in Japanese and Belarusian populations1212 Conditional analysis in Japanese and Belarusian populations
Takahashi et al. 2016 demonstrated that rs965513 and rs1867277 have independent effects on PTC risk confirmed that rs965513 and rs1867277 contribute independently to thyroid cancer risk, particularly evident in populations where linkage disequilibrium between the variants is weaker. Among Europeans, the two variants are in moderate LD, making it harder to separate their effects — but in East Asians and Japanese, their independence is clear.

Individuals carrying risk alleles at both rs965513 and rs1867277 may have compounded thyroid cancer susceptibility through complementary mechanisms: rs965513 reduces FOXE1 expression via the PTCSC2 lncRNA pathway, while rs1867277-A increases FOXE1 expression through USF1/USF2 recruitment. The apparently contradictory directionality suggests these variants affect different aspects of FOXE1 regulation — one quantitative (expression level) and one qualitative (transcriptional context and timing).

Nutrient Interactions

selenium increased_need
iodine altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG Typical Thyroid Risk Normal

No increased thyroid cancer risk from this variant — standard FOXE1 promoter regulation

You have two copies of the G allele, the common protective allele at this locus. This genotype is found in approximately 40% of Europeans and over 77% of East Asians. Your FOXE1 promoter does not recruit USF1/USF2 transcription factors at position -283, and you have baseline FOXE1 transcriptional regulation. You do not carry the variant associated with increased thyroid cancer susceptibility at this site.

AG Intermediate Thyroid Cancer Risk Intermediate

One copy of the FOXE1 promoter risk allele — moderately increased papillary thyroid cancer risk

With one A allele and one G allele, you have an intermediate level of USF1/USF2- mediated FOXE1 transcriptional activation. The additive inheritance pattern means one risk allele provides approximately half the total risk effect of having two. Multiple meta-analyses place the heterozygous OR at approximately 1.4-1.6 for papillary thyroid cancer. This is a common genotype — nearly half of Europeans carry it — and the absolute risk increase is small given the baseline low incidence of thyroid cancer. However, the risk becomes more relevant in the context of additional factors such as family history or radiation exposure.

AA High Thyroid Cancer Risk High Risk

Two copies of the FOXE1 promoter risk allele — approximately 2-fold increased papillary thyroid cancer risk

The rs1867277 AA genotype creates two copies of a USF1/USF2 binding site in the FOXE1 5' UTR that is absent in the G allele. This enhanced transcription factor recruitment increases FOXE1 expression in a context that may promote epithelial-to-mesenchymal transition in thyroid cells. Studies in Turkish PTC patients found AA carriers had significantly higher rates of capsular invasion (OR 2.97), lymph node metastasis (OR 2.46), and advanced stage (OR 4.13) compared to GG, suggesting this variant influences not only cancer risk but also tumor aggressiveness. In Chernobyl-exposed children, the variant amplified radiation-related thyroid cancer risk (OR 1.55), indicating a gene-environment interaction with ionizing radiation.